Radioligand Therapy Platform Innovation Spotlighted at XDC 2026

According to a recent LinkedIn post from C Ray Therapeutics, the company is co-organizing the International RDC Sub-Forum at XDC 2026 in Chengdu, China, focused on radioligand therapy (RLT) design. The post highlights a keynote presentation by Navigo Proteins’ Chief Development Officer, Chris-Carol Bremer, on innovative ligand-based radiopharmaceuticals and alternative protein scaffolds.

The post suggests growing interest in moving beyond traditional antibody-based targeting, emphasizing ultra-small protein scaffolds that may better align pharmacokinetics with short half-life isotopes such as Pb-212 and Ac-225. For investors, this focus points to a potential competitive edge through differentiated RLT platforms that could improve therapeutic index and safety profiles.

As described in the post, the technical themes include achieving antibody-like affinity with faster clearance, site-specific conjugation for precise isotope loading, and engineering ligand kinetics to reduce off-target exposure. If such approaches translate into superior clinical outcomes, companies positioned in this niche could attract strategic partnerships with radiopharma manufacturers and big pharma.

The hosting and co-organizing role at an international conference may also indicate C Ray Therapeutics’ ambition to act as a connector between European protein engineering and Asian radiopharmaceutical manufacturing. This visibility could enhance the company’s deal-flow prospects, licensing opportunities, and access to cross-border capital as the RLT segment continues to attract investment interest.

For the broader sector, the post underscores an emerging shift from merely discovering new isotopes to optimizing delivery vehicles as a key value driver. Should ultra-small scaffolds or similar technologies gain traction, incumbents reliant on antibody-based RLT may face pressure to partner, license, or acquire to remain competitive in the evolving radiopharmaceutical landscape.